WhisperCare AI

Market Problem:

Healthcare organizations are under pressure from two directions at once: clinical complexity is rising, while   administrative capacity is being consumed by manual coordination work. Prior authorization is the clearest   example. Every delayed approval, incomplete packet, repeated denial, or missed notification creates measurable   cost. It slows revenue, frustrates physicians, disrupts patients, and creates avoidable risk for health systems and   pharmaceutical manufacturers and supplier stakeholders. The CMS mandates for 2027 to improve transparency and speed prior authorization determinations compounds this pressure. Pharmaceutical manufacturers and suppliers companies face a related challenge. They invest heavily to bring high-value therapies to market, yet  patient access can stall inside disconnected provider, payer, pharmaceutical manufacturers and suppliers, and documentation workflows.  Commercial teams, access teams, medical affairs, and patient-services organizations need better intelligence on  where therapy journeys break down and which interventions move patients toward appropriate care faster.  

The operational mechanics of prior authorization represents a national opportunity. Repeated denials, step therapy requirements, fax-heavy workflows, missing documentation, appeal cycles, and benefit confusion consume expensive staff time while delaying medically appropriate care. In therapeutic areas where each approved patient matters economically and clinically, even modest acceleration creates meaningful value. WhisperCare is positioned to turn that acceleration into a measurable enterprise workflow advantage.

WhisperCare’s product strategy is to become the real-time intelligence and execution platform that sits across fragmented healthcare workflows. The platform ingests and organizes relevant clinical, operational, and patient context data; turns it into structured workflow intelligence; and activates that intelligence through authorization, oversight, escalation, and reporting workflows.

• Authorization acceleration: automate the assembly, validation, routing, and monitoring of prior authorization packets in high-value therapeutic areas.
• Clinical oversight: detect operational gaps, quality failures, missing notifications, and patient-risk signals before they become enterprise trust events.
• Patient-risk escalation: identify patients whose therapy access, diagnostic follow-up, or care coordination risk requires immediate intervention.
• Enterprise workflow execution: create auditable, measurable workflows that connect providers, pharmaceutical manufacturers and supplier stakeholders, patient-services teams, and infrastructure partners.
• Strategic analytics: reveal where revenue, access, adherence, and operational trust are being lost across the patient journey.

The platform is being sold as business infrastructure, not software ornamentation. Every module connects to a buyer-visible outcome: faster approvals, cleaner documentation, fewer workflow failures, stronger compliance posture, better patient escalation, and clearer visibility for pharmaceutical manufacturers and suppliers and health-system leaders. That discipline keeps product development aligned with the problems customers will immediately pay to fix

John Fraser (Co-CEO): Serial healthcare technology founder and operator with a proven record of building category-defining platforms. As founder and CEO of multiple health tech companies—including Ability Network, acquired for $1.2B—he has repeatedly translated complex market needs into scalable products, durable revenue, and successful exits.

Dr. Russell Amundson (Chief Medical Officer and Co-CEO): Clinical leader combining frontline physician judgment with national payer expertise. Former neurological surgeon and Senior Medical Director at UnitedHealthcare, he brings deep prior-authorization knowledge that strengthens clinical quality, accelerates decision confidence, and supports enterprise-scale adoption.

Dr. David Parker (Director of Clinical Research): Veteran clinician-researcher with deep expertise in epidemiology, outcomes research, and evidence generation. An EIS alumnus at the CDC and former senior researcher at HealthPartners Institute, he adds scientific discipline and clinical validation that de-risk product claims and reinforce payer and provider trust.

Marc Rozycki (CTO): Enterprise technology architect with a track record of designing resilient, high-performance platforms in regulated environments. At Wells Fargo, he served across developer, technology management, and enterprise architecture roles, bringing the system rigor required to scale secure, mission-critical healthcare AI infrastructure.

Advisory Board Members

Amir Yazdavar (Lead AI Engineer, American Express): AI and data science leader who turns advanced research into production-grade healthcare intelligence. Former Principal Data Scientist at Optum, Change Healthcare, and Peerlogic, with research experience across BOSCH, Weill Cornell, Cornell, ISI-USC, and NIH—bringing both technical depth and enterprise execution discipline.

Saurabh Bhargava (Former UnitedHealthcare/Optum AI & Product Leader): Healthcare AI and product executive with 20+ years building high-impact platforms across prior authorization, utilization management, risk, and quality. Combines deep health economics expertise with product leadership to accelerate commercialization, drive measurable ROI, and scale adoption across payer and provider ecosystems.

Dr. Ranyan Lu, MD, PhD, MBA (Former VP, UnitedHealthcare & Horizon BCBSNJ): Seasoned healthcare analytics executive with 20+ years leading clinical performance, prior authorization, and predictive strategy at national scale. Former Vice President at Horizon BCBSNJ and UnitedHealthcare, where she led enterprise analytics for tens of millions of members and helped shape industry measurement standards.

This is not a thinly staffed Silicon Valley experiment looking for a problem. WhisperCare is led by operators, clinicians, payer executives, researchers, and enterprise architects who have already built and scaled serious healthcare and technology businesses. The team brings direct experience from billion-dollar company creation, the largest healthcare insurer in the United States, national payer analytics, clinical research, and regulated enterprise systems.

That credibility is central to the business plan. Prior authorization, patient access, clinical oversight, and operational trust are not problems that can be solved by clever software alone. They require clinical judgment, payer knowledge, health-system pragmatism, evidence discipline, and infrastructure that can survive enterprise scrutiny. WhisperCare’s core five-person team was built around exactly those requirements.

• Dr. Russell Amundson, Chief Medical Officer and Co-CEO: former neurological surgeon and National Medical Director at UnitedHealthcare, VP of Data Science on Optum’s AI team - bringing frontline physician judgment, national payer expertise, and deep prior-authorization operating knowledge.
• John Fraser, Co-CEO: serial healthcare technology founder and operator; founder/CEO of Ability Network, acquired for $1.2B, with a proven record turning complex healthcare infrastructure needs into scalable products and successful exits.
• Marc Rozycki, CTO: enterprise systems architect with Wells Fargo experience, bringing the architecture discipline required for secure, resilient, high-performance healthcare AI infrastructure.
• Dr. David Parker, Director of Clinical Research: CDC Epidemic Intelligence Service alumnus, occupational medicine clinician, and former senior researcher at HealthPartners Institute, adding epidemiology, outcomes research, and evidence-generation rigor.
• Dr. Ranyan Lu, MD, PhD, MBA: Healthcare physician and seasoned healthcare analytics executive with more than 20 years of clinical performance, prior authorization, and predictive strategy leadership, including former Vice President roles at UnitedHealthcare and Horizon BCBSNJ.

The team’s message to customers and investors should be explicit: WhisperCare has the technical product, the payer DNA, the clinical credibility, and the company-building experience to make prior authorization and operational trust a national platform category. The initial funding is designed to accelerate a platform already built with substantial founder investment, not to finance a speculative concept from zero.